Quarterly report pursuant to Section 13 or 15(d)

Note 21 - Segment Information

v3.20.1
Note 21 - Segment Information
3 Months Ended
Mar. 31, 2020
Notes  
Note 21 - Segment Information

Note 21 – Segment Information

 

The Company is an operating, acquisition, and investment business. Subsidiaries in which the Company has a controlling financial interest are consolidated. The Company has determined that there are two reportable segments; 1) the cannabis and medical marijuana segment which includes the cost basis of membership interests of Electrum, the contractual interest in the Electrum legal recovery, the fair value of convertible notes receivable and accrued interest from NeuCourt, the notes receivable from G Farma, the contractual interest in the G Farma legal recovery, the equity in G Farma Equity Entities, finance leases to G Farma and finance leases to Pueblo West, the operation of subsidiaries in the cannabis and medical marijuana sector, and in 2019, included the fair value of cannabis stock securities investments, and 2) the Company’s legacy investment in WCI which works with business park owners, governmental centers, and apartment complexes to reduce their facility related operating costs. The Company also had a certain small cancer-related legacy investment until March 2018, a small investment in General Dynamics Corp. (NYSE: GD), an aerospace and defense corporation, and an investment in note receivable from a non-affiliated party that is included in the Corporate and Eliminations section below.

 

 

 

Cannabis and

Medical

Marijuana

Segment

 

Facility

Operations

Related

 

Corporate

and

Eliminations

 

Consolidated

Three months ended March 31, 2020

 

 

 

 

 

 

 

 

Net revenue

$

12,538

$

1,136,924

$

-

$

1,149,462

Operating income (loss)

 

(8,905)

 

34,176

 

(261,994)

 

(236,723)

Interest income

 

980

 

-

 

18,423

 

19,403

Interest expense

 

-

 

8,471

 

(1,134))

 

7,337

Property additions

 

-

 

3,329

 

-

 

3,329

Depreciation and amortization

 

-

 

2,640

 

1,202

 

3,842

 

 

 

 

 

 

 

 

 

Three months ended March 31, 2019

 

 

 

 

 

 

 

 

Net revenue

$

120,089

$

955,906

$

-

$

1,075,995

Operating income (loss)

 

(606,697)

 

17,179

 

(266,726)

 

(856,244)

Interest income

 

20,679

 

3

 

21,898

 

42,580

Interest expense

 

-

 

5,657

 

(1,134)

 

4,523

Property additions

 

-

 

8,159

 

-

 

8,159

Depreciation and amortization

 

-

 

2,653

 

2,932

 

5,585

 

The following table reconciles operating segments and corporate-unallocated operating income (loss) to consolidated income before income taxes, as presented in the unaudited condensed consolidated income statements:

 

 

 

Three Months Ended

March 31,

 

 

2020

 

2019

Operating loss

$

(236,723)

$

(856,244)

Interest income

 

19,403

 

42,580

Gain (loss) on investments

 

(10,206)

 

(1,569,881)

Interest expense

 

(7,337)

 

(4,523)

Other income

 

12,084

 

-

 

 

 

 

 

Income (loss) before income taxes

$

(222,779)

$

(2,388,068)